GlassScriptPhysician profile
David H Alpert
NPI 1972529840
$964.87
in general payments reported to CMS, 2019-2025
14 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.74 · 2020: $87.30 · 2021: $86.65 · 2023: $197 · 2024: $421 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $155.14 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $127.28 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $126.37 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $99.55 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $89.18 | 2019-2023 | Eliquis, Camzyos |
| Pfizer INC. | $72.76 | 2024-2025 | |
| Shield Therapeutics INC | $62.29 | 2024 | |
| Amgen INC. | $59.90 | 2023-2025 | Evenity, Repatha, Prolia |
| Biohaven Pharmaceuticals, INC. | $37.37 | 2020-2021 | |
| Dexcom, INC. | $33.43 | 2023-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $32.90 | 2021-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $29.57 | 2020-2024 | Veozah |
| Boston Scientific Corporation | $23.87 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alpert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.